“DCGI has made it mandatory for all manufacturers and importers who have obtain new drug permission to submit Periodic Safety Update Reports of new drug every six months for the first two year and for the subsequent two years it should be submitted annually”.
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..